A trial looking at stereotactic radiotherapy and niraparib for ovarian cancer (SOPRANO)

This trial is looking at stereotactic radiotherapy by itself and stereotactic radiotherapy followed by niraparib for ovarian cancer that has started to grow again.

It is open to women who have:

• ovarian cancer

• fallopian tube cancer

• primary peritoneal cancer

And:

• your cancer has started to grow again

• you were taking a PARP inhibitor or the PARP inhibitor was the last treatment you had that reached your whole body (systemic treatment)